LEU
Centrus Energy Corp.Thesis. Centrus is the only US-owned commercial enrichment capacity and the sole domestic HALEU supplier, now anchored by a $1.07B DOE task order and a landmark Oklo HALEU LoI with potential prepayments. The stock has de-rated 64% from its high on lumpy quarterly deliveries and sector rotation out of story-stocks, but $690M net cash and 22% short interest set up an asymmetric re-rate if commercial HALEU volumes materialize. We accumulate on weakness while respecting a still-rich EV/EBITDA.
Scoreboard
At $165.64, LEU sits just 6.6% off its 52-week low ($144.65) and a brutal 64.3% below its $464.25 high, with a $3.26B market cap against a $2.57B EV thanks to $1.87B cash. Price trades well below both the 50-day ($183) and 200-day ($245) averages — a decisive downtrend. Consensus mean target of $274 implies 65.6% upside, but note the recent PT cuts (UBS to $170, Roth to $195) that better bracket near-term reality.
QoQ Changes
Q1 2026 revenue fell to $76.7M from $146.2M in Q4 2025 (-47.5% QoQ), reflecting the SWU/uranium delivery lumpiness inherent to the LEU segment. Basic EPS of $0.51 (GAAP) missed the prior $0.94, yet the Finnhub-adjusted $1.05 crushed the $0.557 consensus by 88.4% — timing, not deterioration.
Gross margin compressed to 25.7% trailing, with operating margin at essentially breakeven (-0.26%) and EBITDA margin a thin 7.56% — Q3 2025 even printed a negative gross profit (-$4.3M), underscoring quarter-to-quarter volatility. Blended profitability is being carried by uranium price tailwinds and contract mix rather than steady operating leverage.
FCF margin is negative (-2.4%) with an implied FCF yield of -0.33%, as enrichment capacity expansion consumes capital ahead of commercial HALEU revenue. Operating cash conversion remains hostage to delivery timing, so treat single-quarter FCF as noise, not signal.
Cash of $1.87B ($94.96/share) against $1.18B debt yields $690M net cash and a formidable 5.72x current ratio / 4.76x quick ratio. Debt/equity screens optically high at 152% but is immaterial given the net-cash position and DOE cost-share funding.
Trailing P/E of 63x and EV/EBITDA of 75x are steep against a forward P/E of 41.7x and P/S of 7.2x — the multiple compression to forward reflects expected earnings normalization. Versus its own 200-day price this is cheaper on tape, but the EBITDA multiple leaves no margin for execution slips.
The last 60 days delivered three needle-movers: a signed $900M (up to $1.07B) DOE task order pivoting from demonstration to commercial-scale HALEU, an Oklo HALEU supply LoI (deliveries from 2029, possible prepayments), and S&P SmallCap 600 inclusion effective July 14. Headcount sits at 467 with ~1,300 new Ohio/Tennessee construction and operating jobs tied to the expansion.
Ownership & Insider Activity
Institutions own 85.9% (BlackRock 7.85%, State Street 7.41%, Mirae, Van Eck), and short interest is elevated at 22.45% of float / 4.74 days-to-cover — a coiled spring for any positive HALEU catalyst. Finnhub Form 4 data shows June activity was almost entirely compensation grants (code A: directors +757 each, CEO Vexler +1,712), not conviction buying. The only open-market print is CFO Tinelli's $62,286 sale at $203.55 on May 11 — modest, but the sole cash-signal is a sell, tempering the insider read to neutral-to-slightly-negative.
Recent Insider Transactions
| Date | Insider | Position | Shares | Value |
|---|---|---|---|---|
| 2026-06-18 | JONAS TINA W | Director | 757 | $0.00 |
| 2026-06-18 | DONALD KIRKLAND H | Director | 757 | $0.00 |
| 2026-06-18 | ROTHROCK RAY A | Director | 757 | $0.00 |
| 2026-06-18 | WILLIAMS MIKEL H | Director | 757 | $0.00 |
| 2026-06-18 | MADIA WILLIAM J | Director | 757 | $0.00 |
| 2026-05-11 | TINELLI TODD M | Chief Financial Officer | 306 | $62.3K |
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-03-31 Q1 | $1.05 | $0.56 | +$0.49 | +88.44% |
| 2025-12-31 Q4 | $0.79 | $1.42 | $-0.63 | -44.37% |
| 2025-09-30 Q3 | $0.19 | $0.12 | +$0.07 | +52.12% |
| 2025-06-30 Q2 | $1.59 | $0.82 | +$0.77 | +94.78% |
Beat consensus in 3 of the last 4 quarters (75% beat rate) with a hefty average surprise of +47.7%, including +88.4% in Q1 2026 and +94.8% in Q2 2025 — signaling either durable execution or, more likely, chronic analyst under-modeling of lumpy delivery timing.
Surprises are large but erratic (the -44.4% Q4 2025 miss interrupts the beats), so the pattern reads as analyst miscalibration to delivery cadence rather than a widening, guidance-managed beat streak — high variance, low predictability.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 3 | 10 | 6 | 0 | 0 | |
| 2026-06 | 3 | 9 | 6 | 0 | 0 | |
| 2026-05 | 3 | 11 | 6 | 0 | 0 | |
| 2026-04 | 3 | 11 | 6 | 0 | 0 |
The Finnhub series shows a mild bullish erosion: Buy ratings slipped from 11 (Apr/May) to 10 (Jul) while Strong Buy held at 3 and Hold steady at 6, with zero Sell/Strong Sell throughout. Net composition remains firmly constructive (13 Buy-side vs 6 Hold), but the marginal drift is lower alongside the UBS and Roth PT cuts.
Momentum is flat-to-slightly-bearish over the visible window — no downgrades, but bullish conviction is fading at the margin (drift -1).
Seven Essential Metrics
EBITDA margin just 7.56% and operating margin breakeven (-0.26%), though ROE is a respectable 12.25% and profit margin 13.4% on tax/other items.
Revenue growth of only 4.9% and earnings down 71.9% YoY, but forward story is volume-driven HALEU ramp not visible in trailing figures.
FCF margin -2.4% and FCF yield -0.33% as expansion capex front-runs commercial revenue.
$690M net cash and 5.72x current ratio dwarf the optically high 152% debt/equity.
Beta 1.36, 22.45% short interest and a 64% drawdown mean high volatility, but net cash removes solvency risk.
Forward P/E 41.7x, EV/EBITDA 75x and P/S 7.2x price in flawless HALEU commercialization.
No buyback signal; potential Oklo prepayments fund growth without visible dilution, though equity raises remain a capacity-funding risk.
Capital is fully directed at enrichment capacity expansion, not distributions.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
CCJ Cameco Corp. | ~30% | ~20% | ~15% | <1x | ~40x |
UEC Uranium Energy Corp. | negative | high/erratic | negative | Net cash | n/a |
UUUU Energy Fuels Inc. | negative | ~25% | negative | Net cash | n/a |
NXE NexGen Energy Ltd. | n/a (pre-revenue) | n/a | negative | Net cash | n/a |
Within the uranium complex, LEU is the profitable-but-lumpy enricher that sits between cash-generative Cameco and the loss-making developers (UEC, UUUU, NXE) that the market is now punishing for cash burn. Its differentiator is structural: enrichment and HALEU, not mining — Centrus has no direct US-listed pure-play competitor for domestic HALEU. That scarcity justifies a premium, but the 75x EV/EBITDA versus Cameco's more mature multiple demands proof of commercial volumes.
Business & Strategy
Two segments: Low-Enriched Uranium (SWU, natural UF6, uranium concentrates and conversion, enriched product) drives the bulk of revenue, while Technical Solutions delivers engineering/operations services — including the DOE HALEU work. The recent pivot from a demonstration contract to the $1.07B commercial-scale DOE task order marks a strategic shift toward recurring, government-anchored enrichment revenue.
Nuclear utilities across the US, Japan, and the Netherlands, plus US government agencies and next-gen reactor developers such as Oklo.
SWU and uranium product sales to utilities under long-dated contracts, government cost-share and task-order funding for HALEU, and technical/engineering service fees. Potential customer prepayments (Oklo LoI) could pre-fund capacity.
Enrichment capacity buildout capex, centrifuge cascade operations, uranium feedstock costs, and skilled labor at the Piketon, Ohio and Oak Ridge, Tennessee facilities.
Centrus operates the only US-owned, NRC-licensed commercial enrichment capability and is the sole domestic HALEU producer — a regulatory and geopolitical moat sharpened by the ban on Russian enriched uranium imports. Replicating licensed centrifuge capacity requires years and government backing, making this a genuine national-security franchise rather than a commodity price-taker.
Monetary-Policy Sensitivity
- Long-duration growth equity — lower discount rate lifts DCF of 2029+ HALEU cash flows
- High short interest amplifies upside in risk-on rate-cut tape
- Cheaper financing for multi-year capacity expansion capex
As a pre-commercialization growth name with cash flows weighted to 2029 and beyond, LEU behaves like a long-duration asset that benefits disproportionately from falling discount rates. A dovish pivot would also fuel small-cap risk appetite, pressuring the 22% short base — but rate cuts are a secondary driver behind HALEU execution.
SWOT Analysis
- Only US-owned commercial enrichment / sole domestic HALEU supplier — deep regulatory moat
- $690M net cash, 5.72x current ratio — fortress balance sheet funds expansion
- $1.07B DOE task order plus Oklo LoI anchor a commercial HALEU pipeline
- S&P SmallCap 600 inclusion (Jul 14) forces passive buying into a thin float
- Violently lumpy quarterly revenue (Q1 rev -47.5% QoQ) obscures the trend
- Negative FCF and 7.6% EBITDA margin — capital-intensive ramp
- Expensive on forward multiples (41.7x P/E, 75x EV/EBITDA)
- Insider cash activity skews to selling (CFO sale) not buying
- Commercial-scale HALEU demand from SMR/advanced reactor fleet (Oklo and others)
- Russian enriched-uranium import ban reshoring enrichment to Centrus
- Potential customer prepayments de-risk capacity capex
- Uranium price cycle and nuclear renaissance / AI-power demand tailwind
- Execution/timeline slippage on HALEU commercialization to 2029
- Government funding or policy reversal risk on DOE cost-share
- Sector rotation punishing story-stocks (32% peer drawdowns)
- Equity issuance to fund expansion could dilute holders
Catalysts & Event Risks
- 2026-07-14S&P SmallCap 600 inclusion
Effective before the open on July 14, forcing passive index buying into an 18.3M-share float.
- Q3 2026Q2 2026 earnings
Next print tests whether the DOE contract and delivery cadence stabilize the lumpy revenue line.
- 2026-12-31DOE task-order milestones
Progress on the $1.07B expansion (Ohio/Tennessee jobs) validates the pivot to commercial-scale production.
- 2027-01-01Oklo HALEU definitive agreement
Conversion of the June LoI into a binding contract with potential prepayments would de-risk 2029 deliveries.
- 2029-01-01First commercial HALEU deliveries
The structural inflection — Oklo/utility HALEU shipments begin, converting story into recurring revenue.
The July 14 index inclusion is a near-term technical tailwind, but the value-defining catalysts are contractual — a binding Oklo agreement and DOE milestone execution matter far more than any single quarter. Watch for prepayment structures, which would transform the funding and de-risking calculus.
Technical Analysis
LEU is in a clear downtrend, trading below both the 50-day ($183) and 200-day ($245) moving averages at a position of just 6.6% within its 52-week range. Immediate support is the $144.65 52-week low; a break there opens air below, while reclaiming the $183 50-day is the first sign of stabilization. The setup is high-risk, high-reward: buying near multi-quarter lows against a 22% short base offers asymmetric squeeze potential, but there is no confirmed reversal yet — scale in rather than chase. Risk-reward favors accumulation for patient capital, not a momentum entry.
Verdict
Macro context. The nuclear renaissance — driven by AI/datacenter power demand, electrification, and Western energy security post the Russian enriched-uranium import ban — is a durable multi-year tailwind, though the uranium complex is mid-correction with capital rotating from cash-burning developers to profitable, execution-proven names. Centrus, as the sole domestic HALEU franchise, is uniquely positioned to benefit from reshoring policy regardless of near-term spot uranium volatility.
Centrus is a genuine national-security monopoly — the only US-owned commercial enricher and sole domestic HALEU supplier — now trading 64% off its high with $690M net cash and 22% short interest, an asymmetric setup for patient capital. The bear case is real: forward multiples are rich (41.7x P/E, 75x EV/EBITDA), revenue is violently lumpy, FCF is negative, and the payoff hinges on 2029 commercialization that the market is impatiently discounting. We rate ACCUMULATE with a $228 target (~38% upside), scaling in near multi-quarter lows ahead of the July index inclusion, a binding Oklo agreement, and DOE milestone proof — while sizing for the volatility this structural story demands.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 7:08:39 AM